CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the ...

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in Q4 2024, and Genenta expects to treat six patients by the end of the first half of 2025, while continuing progress ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

Foundery Immune Studio, LLC, a biotechnology venture studio focused on translating immunology discoveries into medicines, ...

Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 -- Clinical data update expected in Q2 2025 - ...

Study uncovers how Cancer-associated Fibroblasts influence tumour immunity, paving the way for targeted cancer treatments.

An international team of UK and US scientists has discovered that the activity of macrophages – a type of white blood cell that engulf pathogens and cancer cells – can be used to predict whether or ...

Neutrophils are the most abundant white blood cells in the human body, primarily recognized for their essential roles in fighting infections and regulating inflammation. However, their involvement in ...

A pioneering study has uncovered the complex and dual roles of neutrophils in cancer development, demonstrating their ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a ...

The human immune system is a complex network of cells and signals that guards against disease, yet in the case of cancer, it ...